Drug Trial Radar · NCT03679143
The Safety, Tolerability and Pharmacokinetic Study of ZSP1273 in Healthy Volunteers.
Last checked: Nov 19, 2026Latest source record: Aug 14, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
103
Actual
Start
Sep 20, 2018
Primary completion
Mar 19, 2019
Study completion Apr 26, 2019
Sponsor
- Lead sponsor
- Guangdong Zhongsheng Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 20, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single center,double-blind,randomized,parallel design, single and multiple dose trial to evaluate the pharmacokinetics(PK), safety and tolerability of ZSP1273,and the effect of food on ZSP1273 Pharmacokinetics.
Conditions
- Influenza
Interventions
ZSP1273 100 mgDrug
ZSP1273 tablet administered orally once daily under fasted condition
Placebo 100 mgDrug
Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state.
ZSP1273 200 mgDrug
ZSP1273 tablets administered orally once daily under fasted condition
Placebo 200 mgDrug
Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
ZSP1273 400 mgDrug
ZSP1273 tablets administered orally once daily in the fasting state
Placebo 400 mgDrug
Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state
ZSP1273 600 mgDrug
ZSP1273 tablets administered orally once daily under fasted condition
Placebo 600 mgDrug
Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
ZSP1273 900 mgDrug
ZSP1273 tablets administered orally once daily in the fasting state
Placebo 900 mgDrug
Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
ZSP1273 1200 mgDrug
ZSP1273 tablets administered orally once daily in the fasting state
Placebo 1200 mgDrug
Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state
ZSP1273Drug
ZSP1273 tablets administered orally once daily under fasted or fed condition
PlaceboDrug
Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition
ZSP1273 Low DoseDrug
ZSP1273 tablets administered orally once daily under fasted or fed condition for 5 Days.
PlaceboDrug
Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition for 5 Days.
ZSP1273 Median DoseDrug
ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
PlaceboDrug
Participants will receive placebo matching to ZSP1273 orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
ZSP1273 High DoseDrug
ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
PlaceboDrug
Participants will receive placebo matching to ZSP1273 orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and severity of treatment-emergent adverse events (TEAEs) and Serious Adverse Events(SAE)Time frame: At day 5, 9, 12 days post first dosing for SAD, MAD, FE part respectively
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Hospital of Jilin University
Changchun, Jilin, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.